source
- Teva R&D chief Eric Hughes resigns, company taps innovative medicines head as interim leadTeva announced that its chief scientific officer for research and development, Eric Hughes, M.D., Ph.D., will leave the company. Hughes, who joined Teva in 2022 as executive vice president of globa…
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…